Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. The company has claimed across-the ...

Atopic dermatitis (AD) is a highly prevalent chronic ... often negatively affect their day-to-day and long-term well-being. Lebrikizumab, a monoclonal antibody that inhibits an interleukin named ...

Medscape Medical News, October 01, 2024 EADV 2024 Atopic Dermatitis Control on Biologic Persists Over 3 Years In a 3-year extension of the pivotal trials that provided lebrikizumab with an ...

The US approval of Eli Lilly’s Ebglyss (lebrikizumab) in September 2024 places the company in a competitive position in the atopic dermatitis (AD) market. AD, also known as eczema, is a chronic ...

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

In addition, Thaçi added, the “safety data support the long-term use of nemolizumab for the treatment of adolescent and adult patients with moderate to severe atopic dermatitis.” The current ...

The most common form of eczema is atopic dermatitis, and the terms are often used interchangeably. The condition often crops up during childhood, experts said. And while some people outgrow it ...

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA ...

Given atopic dermatitis' negative impacts on quality of life among adolescents, including increased suicidality, "there remains a need for treatments available to this population," the authors ...

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis with upadacitinib is safe and effective through 76 weeks.